Navigation Links
World Diabetes Day Prompts Diopsys to Reach Out

In recognition of World Diabetes Day, Diopsys is lending its voice to the global diabetes community to help raise diabetes awareness and advocacy. The company is reaching out to help educate patients and the healthcare community about the clinical and economic impact of diabetes as well as emphasize the importance of vision testing for people with the disease.

The American Diabetes Association (ADA) released new research earlier this year estimating the total U.S. cost of diagnosed diabetes rose to $327 billion in 2017. There are currently more than 30 million Americans living with diabetes, and their medical expenditures are around 2.3 times greater than those without diabetes. According to the ADA, “The data indicate one of every four health care dollars is incurred by someone with diagnosed diabetes, and one of every seven health care dollars is spent directly treating diabetes and its complications.”

In addition to the systemic complications, diabetes can also cause damage to the blood vessels and the neurons in the eye leading to diabetic retinopathy (DR). Structural abnormalities like microaneurysms and hemorrhages can occur, which can lead to retinal ischemia, vision loss and potentially blindness. According to the International Diabetes Foundation, approximately one in three people with diabetes has diabetic retinopathy and one in ten will develop a vision threatening form of the disease.

Fortunately, evolving treatment standards in DR have proven highly successful at slowing or stopping disease progression, but intervention is most successful when the disease is caught early. Recognizing the signs of DR on clinical examination or with imaging, however, is challenging, and many cases are identified only after permanent damage has occurred. Diopsys provides two different vision tests that can help eye care specialists detect and manage the disease earlier.

The Diopsys® Chromatic Flash Vision Screener helps address the unmet need for early recognition of retinal function changes related to DR with an easy-to-use in-office screening test. Using red-on-blue flash electroretinography (ERG), the new screening test records the electrical potential of the retina to provide quantitative measurements of retinal function. Results are then analyzed against healthy reference range data to help the doctor understand the probability of the patient developing retinopathy.

“In diabetic retinopathy, we know functional changes will likely happen before structural changes, and to now have the ability to measure retinal function with this new test from Diopsys is truly a game changer,” said Nate Lighthizer, OD, FAAO. “It has been very useful as a screening test in our diabetic patients without retinopathy to help guide our management options and follow-up based on the results. The OCT, a structural test, has been utilized as a screener for some time, and the Diopsys test gives us the ability to also use function as a risk indicator.”

In addition to the screener, Diopsys also provides vision tests that help eye care specialists track disease progression and response to treatment. The Diopsys® ffERG / Flicker testing protocols record the retina’s response to flashes of light – reflecting the electrical activity of cone and bipolar cells – and provide objective, functional information about global retinal health. Flicker ERG vision tests use intuitive color-coded reports to help physicians evaluate retinal disease severity, predict retinal ischemia, quantify retinal function loss and recovery, and monitor retinal function for appropriate and timely treatment.

John Wroblewski, MD, a specialist in medical retina, uveitis, surgical retina, and inherited retinal diseases, has said the Diopsys® ffERG / Flicker testing protocols “allow clinicians to establish a functional baseline in diabetic retinopathy, and then follow disease in a way that we can’t otherwise.”

Follow Diopsys on Facebook, Twitter, and LinkedIn to get more facts and figures related to diabetes for World Diabetes Day using the hashtag #WDD2018.

About Diopsys Inc.
As the world leader in modern visual electrophysiology, Diopsys, Inc. ( has done more than any other company to advance the use of electroretinography (ERG) and visual evoked potential (VEP) in the eye care practice. The company’s unique, patented technology provides eye care professionals with objective, functional information about the health of the vision system to aid in the early detection of vision disorders, and post-treatment tracking for enhanced patient management.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. Cold Chain Industry Leader, Modality Solutions, is Silver Sponsor and Exhibitor at Biomanufacturing World Summit
2. CTL Medical to Become World’s Only Provider of Silicon Nitride Spine Products
3. Distinguished Cardiologists and Scientists Honored with 2018 International Academy of Cardiology Awards at the 23rd World Congress on Heart Disease
4. Dr. Deepak L. Bhatt to Deliver Opening Lecture at International Academy of Cardiology, Annual Scientific Sessions 2018, 23rd World Congress on Heart Disease
5. Ram Group Announces Worlds First Full-Body Biometric Authentication Technology
6. to Host the Worlds First Hack the Genome Hackathon
7. 4Dx Announces Preliminary Clinical Trial Data at Prestigious World Lung Imaging Event
8. EyeLock führt sichere biometrische Möglichkeit zur Iris-Erkennung für mobile Plattform Qualcomm Snapdragon 835 auf dem Mobile World Congress 2017 vor
9. EyeLock to Demonstrate Secure Iris Biometric Capability on the Qualcomm Snapdragon 835 Mobile Platform at Mobile World Congress 2017
10. Biometrics Market Forecasts: Global Unit Shipments and Revenue by Biometric Modality, Technology, Use Case, Industry Segment, and World Region: 2016-2025
11. New World Record for Fingerprint Recognition Software
Post Your Comments:
(Date:12/5/2018)... ... December 05, 2018 , ... Surgical ... in Nashville, TN, from December 6-9, 2018 at booth #312. AANS/CNS provides Pediatric ... integrates throughout the treatment continuum – from the consultation, to surgical planning, and ...
(Date:12/5/2018)... ... 04, 2018 , ... Urological Associates of Southern Arizona today ... Excellence. The designation recognizes that Dr. Choi has achieved a high level of ... care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH. ...
(Date:11/29/2018)... (PRWEB) , ... November 29, 2018 , ... ... in Semba Biosciences with the intention of acquiring full ownership. The transaction was ... Agreement was executed on November 14, 2018. “We are extremely pleased to team ...
Breaking Biology News(10 mins):
(Date:12/5/2018)... DIEGO (PRWEB) , ... December 05, 2018 , ... Leading ... introduces an all-new, how-to guide with his “The Referral Playbook: How to Increase ... 100% of the book proceeds will go to the Alzheimer’s Foundation of America (AFA). ...
(Date:12/5/2018)... CHARLOTTESVILLE, Va. and LONDON (PRWEB) , ... ... ... Atlantic Research Group (ARG), an established North American full-service contract research organization ... CRO. Effective immediately, the transaction significantly strengthens ARG’s reach and experience in ...
(Date:11/27/2018)... SPRINGS, Ga. (PRWEB) , ... November 27, 2018 , ... ... can now visit Dr. Dan Myers’ practice for treatment, with or without a referral. ... cosmetic procedures and tools, including porcelain veneers, dental implants, bridges and custom crowns. ...
(Date:11/20/2018)... ... 19, 2018 , ... Patients with missing teeth in Sandy Springs, GA, Alpharetta, ... Dan Myers at THE DENTIST Centers without a referral. Dr. Myers is a skilled ... 20 years. He now offers skilled dental care in two practice locations THE DENTIST ...
Breaking Biology Technology: